Source comparison
Tesamorelin vs Egrifta SV: Clinical and Research Context Comparison
Active Molecule Tesamorelin (44-amino-acid GHRH analogue) Pharmacologically identical. Same receptor binding, same mechanism FDA Approval Status FDA-approved for HIV-associated lipodystrophy Not FDA-approved; intended for research use only Approval covers spec
This comparison does not assign a generated winner or score.
- Active Molecule
- Tesamorelin (44-amino-acid GHRH analogue)
- Pharmacologically identical. Same receptor binding, same mechanism
- FDA Approval Status
- FDA-approved for HIV-associated lipodystrophy
- Not FDA-approved; intended for research use only
- Approval covers specific indication and manufacturing process, not the molecule's full potential
- Typical Dose
- 2 mg subcutaneously once daily
- 1–2 mg daily (protocol-dependent)
- Clinical dose is standardized; research protocols may explore lower or higher ranges
- Reconstitution
- Sterile water; use within 3 hours
- Bacteriostatic water; stable 7–14 days refrigerated
- Research formulations allow multi-dose use; clinical version prioritizes single-use sterility
- Cost
- $4,000–$6,000/month retail
- $150–$300/month (supplier-dependent)
- Cost differential reflects pharmaceutical manufacturing overhead and patent protection
- Accessibility
- Prescription-only through specialty pharmacies
- Available through research peptide suppliers like Real Peptides
- Access pathways differ. Clinical requires prescriber; research requires institutional affiliation or self-directed study